Gilead Sciences (GILD)
157.19
+3.62 (2.36%)
NASDAQ · Last Trade: Oct 22nd, 4:35 PM EDT
News & Press Releases
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company.
By Gilead Sciences, Inc. · Via Business Wire · October 22, 2026
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
Gilead Sciences, Inc. (Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver Meeting® 2026, hosted by the American Association for the Study of Liver Diseases (AASLD), November 5-9 in Denver, Colorado. The data will examine durability of response, patient-relevant symptoms, and opportunities to better understand long-term disease management across these two rare and serious liver diseases.
By Gilead Sciences, Inc. · Via Business Wire · October 22, 2026
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?fool.com
Both of these ETFs look the part, but only one is truly the better buy for investors.
Via The Motley Fool · October 22, 2026
Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Daymarketbeat.com
Arcus Biosciences (NYSE:RCUS) presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line and later-line clear cell renal cell carcinoma (RCC).
Chief Executive Officer Terry Rosen said the co
Via MarketBeat · October 21, 2026
Gilead Sciences (NASDAQ:GILD) Offers Dividend Investors Quality Income and Valuation Supportchartmill.com
Via Chartmill · October 5, 2026
Gilead Sciences (NASDAQ:GILD) Combines Top Technical Strength With a High-Quality Breakout Setupchartmill.com
Via Chartmill · October 2, 2026
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its HIV and antiviral research and development programs at IDWeek 2026, taking place October 21-24 in Washington, D.C. The 28 presentations, including two oral presentations, will feature research in HIV treatment, HIV prevention and new insights into broader experiences of people living with HIV, as well as emerging antiviral programs.
By Gilead Sciences, Inc. · Via Business Wire · October 19, 2026
1 Unprofitable Stock with Exciting Potential and 2 We Find Risky
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...
Via StockStory · October 19, 2026
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?fool.com
The company's recent momentum continues unabated.
Via The Motley Fool · October 18, 2026
3 Inflated Stocks Walking a Fine Line
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...
Via StockStory · October 16, 2026
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2026 financial results and provide a business update.
By Gilead Sciences, Inc. · Via Business Wire · October 15, 2026
Top S&P500 movers in Wednesday's sessionchartmill.com
Via Chartmill · October 14, 2026
Exploring the top movers within the S&P500 index during today's session.chartmill.com
Via Chartmill · October 14, 2026
Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lensfool.com
PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.
Via The Motley Fool · October 11, 2026
Better Biotechnology ETF: First Trust FBT vs. VanEck BBHfool.com
VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.
Via The Motley Fool · October 10, 2026
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharmafool.com
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
Via The Motley Fool · October 10, 2026
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD)...
Via StockStory · October 7, 2026
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targetsmarketbeat.com
Compugen (NASDAQ:CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event.
President and Chief Executive Officer Er
Via MarketBeat · October 5, 2026
Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBBfool.com
VHT offers broad sector exposure, while IBB concentrates on biotech with higher growth but steeper drawdowns.
Via The Motley Fool · October 5, 2026
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJPfool.com
VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.
Via The Motley Fool · October 2, 2026
Better Healthcare ETF: iShares Biotechnology-Focused IBB vs. Simplify's Broad PINKfool.com
iShares offers lower fees and concentrated biotech exposure with stronger 1-year returns, while Simplify provides broader healthcare diversification and a higher dividend yield.
Via The Motley Fool · September 25, 2026
XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentrationfool.com
XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.
Via The Motley Fool · September 24, 2026
Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?fool.com
VanEck's concentrated 25-stock biotech portfolio surged 40.5% in one year, but Fidelity's diversified 365-holding fund delivered superior risk-adjusted returns with half the volatility.
Via The Motley Fool · September 24, 2026
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYHfool.com
IBBQ offers concentrated biotech exposure with lower costs and stronger recent returns, while IYH provides broader sector diversification and higher dividend income.
Via The Motley Fool · September 22, 2026
1 Cash-Producing Stock on Our Buy List and 2 We Find Risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via StockStory · September 22, 2026